|
Welcome
to Neuro Biomed Inc.
|
 |
Neuro
Biomed, Inc. is a bio-pharmaceutical company committed
to the discovery and development of new drugs to
treat diseases for which there is significant
unmet medical need. Neuro
Biomed pioneers an emerging area of
biotechnology known as regenerative
medicine with a family of neuroprotective
agents and advanced
controlled release drug formulations for
better patient care.
|
| |
Neuro Biomed's
pharmaceutical
products are designed to support the
regeneration of cells and tissue with its
ability to repair damage caused by disease,
trauma or age. Innovative
therapies based on this knowledge can be used to
a broad range of unmet medical needs, including
those associated with neurological disorders
such as: traumatic
brain injury, stroke,
Alzheimer's
disease, Parkinson's
disease, Edema,
Multiple
Sclerosis , neuropathic
pain and brain
cancer. |
| |
|
| |
 |
Neuro
Biomed's first drug candidate in
clinical development is
NB-3108, a
neuroprotective and neurogenesis agent.
NB-3108 is a novel
neuroprotective agent for acute
treatment of stroke and traumatic brain
injury (TBI), as well as for
prophylactic treatment of neurological
damage associated with coronary artery
bypass graft (CABG). |
|
| |
The
initial targeted application of NB-3108
is for the treatment of stroke, which is
the third leading cause of death in the
US, Europe, and Japan. Over 500,000
stroke victims are reported every year
in the US alone. There are approximate
500,000 ischemic incidents resulting
from traumatic brain injury and open
heart surgery, such as coronary artery
bypass graft (CABG). |
|
 |
Driven
by its mission to develop drugs with superior
safety and efficacy, Neuro Biomed uses
sophisticated methods of drug design in
combination with advanced
drug delivery system to invent new and to
improve existing therapeutic compounds.
Neurobiomed's focus is in the fast
growing market for new drug delivery
formulations, especially for the
treatment of neurological disorders.
According
to Datamonitor, a leading marketing research
firm, the market size of the global drug
delivery market is in excess of US$66
billion, and is estimated to grow to US$114
billion by 2007.
NanoBio
Drug Delivery System™
Our
patented NanoBio Drug
Delivery System™
is based on the advanced development of the
novel nanostructure bio-electric membrane
for drug delivery and diagnostic
applications.
Neuro Biomed's proprietary technologies have resulted
in products that have increased efficacy and/or
reduced side effects relative to their
precursors and to competing products.
|
| |
|
 |
Neuro
Biomed applies a commercially driven approach to
R&D activities, while seeking to partner
with other pharmaceutical companies to generate
income, share risk and assist in the validation
of the underlying technologies. For further
information, please feel free to
contact
Lloyd L. Tran, Chief Scientific
Officer,
Neuro Biomed Corporation
1290 Parkmoor Avenue, San Jose, CA
95126
Tel. 408-277-3041 Fax.
408-280-6255
info@neurobiomed.com |
|
|
|